N-acetylation phenotype in bladder cancer.
1 N-acetylation phenotype has been examined in 30 patients with bladder cancer and in 27 controls of similar age. 2 59% of controls and 70% of bladder cancer patients were phenotypically 'slow' acetylators. This difference was not significant (P greater than 0.30). 3 Within phenotypes, isoniazed half life was similar in controls and bladder cancer patients. 4 N-acetylation phenotype is unlikely to be a major determinant in the pathogenesis of bladder cancer in the population studied.
D000107:Acetylation; D000368:Aged; D002273:Carcinogens / Q000378:metabolism; D005260:Female; D006207:Half-Life; D006801:Humans; D007538:Isoniazid / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D010641:Phenotype; D001749:Urinary Bladder Neoplasms / Q000209:etiology / Q000235:genetics / Q000378:metabolism*
D002273:Carcinogens; D007538:Isoniazid